ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ablynx
ClinicalTrials.gov Identifier:
NCT01875926
First received: June 10, 2013
Last updated: January 2, 2014
Last verified: January 2014
  Purpose

The overall aims of the study are:

  • To provide additional information on the pharmacokinetics of ALX-0171 by measuring (i) local (bronchoalveolar lavage fluid (BALF)) and systemic (plasma) concentrations of ALX-0171 after oral inhalation, and (ii) systemic (plasma) and urine concentrations after intravenous administration.
  • To further determine the safety and local and systemic tolerability of ALX-0171.
  • To further evaluate local (induced sputum) and/or systemic (serum) immunogenicity of ALX-0171, by analysing the potential occurrence of anti-drug antibodies (ADA).

Condition Intervention Phase
Healthy
RSV Infection
Biological: ALX-0171
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I, Single-centre, Open-label Study to Evaluate the Pharmacokinetics of ALX-0171, Administered by Oral Inhalation or Intravenously, in Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by Ablynx:

Primary Outcome Measures:
  • Pharmacokinetics: concentration of ALX-0171 after oral inhalation in BALF samples and in plasma samples [ Time Frame: Day 1 to Day 9 ] [ Designated as safety issue: No ]
  • Pharmacokinetics: ALX-0171 concentration in plasma and urine after intravenous administration [ Time Frame: Day 1 to Day 4 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability: safety markers [ Time Frame: from signing of Informed Consent Form (ICF) until last follow-up visit (i.e 35 to 42 days after first study drug administration) ] [ Designated as safety issue: Yes ]
    • Lung function test pre- and post-inhalation with 4 mL of ALX-0171 placebo (on Day -1, applicable for oral inhalation only).
    • Lung function tests
    • Physical examination (including physical examination of the lung for oral inhalation)
    • Vital signs
    • 12-lead ECG.
    • Clinical laboratory
    • Limited safety lab (haematology + limited chemistry).
    • Adverse events (AEs) and concomitant medication

  • Immunogenicity: concentration of Anti-Drug Antibodies (ADA)in induced sputum (after oral inhalation only) and serum [ Time Frame: during screening until last follow-up visit (i.e. 35 to 42 days after first study drug administration) ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: June 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALX-0171 Oral Inhalation - Single Dose (SD) Biological: ALX-0171
single dose of 200 mg ALX-0171 via oral inhalation
Experimental: ALX-0171 Oral Inhalation - Multiple Dose (MD) Biological: ALX-0171
repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
Experimental: ALX-0171 Intravenous (IV) Biological: ALX-0171
Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Non-smoking healthy male volunteers, (18-55 years, extremes included).
  2. Good health condition, as determined by medical history, physical examination and clinical laboratory testing
  3. Body mass index (BMI) within normal range: 18.0 ≤ BMI < 30.0 (kg/m2)
  4. Haematology and chemistry parameters within normal range, or showing no clinically relevant deviations (as judged by the Investigator)
  5. Heart rate and/or blood pressure within normal range (as judged by the Investigator)
  6. Electrocardiogram (ECG) within normal range, or showing no clinically relevant deviations (as judged by the Investigator)
  7. Negative urine test for selected drugs of abuse at screening
  8. Negative alcohol breath test upon check-in at study unit
  9. Negative hepatitis panel (including hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (anti-HCV)), and negative human immunodeficiency virus (HIV) antibody screens
  10. Willingness to consent to using an effective contraceptive method (by using 2 methods of contraception in combination with a female partner: at least 1 of the contraception methods must be a barrier contraception method, e.g., condom) during the study and for at least 3 months after last study drug administration
  11. Ability to comprehend and willingness to sign an Informed Consent Form (ICF)

    For oral inhalation only:

  12. Lung function test which shows a Forced Expiratory Volume in 1 second (FEV1) ≥ 90% of predicted value
  13. Ability to retro-breathe with nebulizer
  14. Height between 170 and 190 cm (extremes included)
  15. Ability to produce a sufficient amount of induced sputum (at least 400 μL containing visual sputum plugs) to assess immunogenicity

Exclusion Criteria:

  1. Current smokers, or ex-smokers abstinent from tobacco for less than one year, or a history of smoking more than 10 packs a year
  2. Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing
  3. Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in the absence of febrile episodes, in the last 14 days prior to dosing
  4. History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism or excretion of drugs
  5. Malignancy, or prior malignancy, with a disease-free interval of < 5 years after diagnosis and intervention, except basal cell carcinoma (treated curatively)
  6. Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis.
  7. History of hypersensitivity or allergies to any drug compound, including constituents of ALX-0171
  8. History of previous administration of ALX-0171, or any other inhaled biologic or drug targeting the Respiratory Syncytial Virus (RSV) F protein. In any other case of use of biologics: at least 6 months before administration of first study medication, or the time of duration of the pharmacodynamic effect, or 10 times the half-life of the respective drug, whatever is longer
  9. Receipt of any investigational drug within 60 days prior to dosing
  10. Intake of prescribed or over-the-counter medication within 14 days prior to dosing (≤ 3 g/day paracetamol is allowed)
  11. History or presence of alcohol or drug abuse
  12. Blood donation (> 500 mL) or a comparable blood loss within three months prior to dosing
  13. Planned donation of germ cells, blood, organs, bone marrow during the course of the study or within 6 months thereafter
  14. Any other condition or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study
  15. Vulnerable subjects (e.g., persons kept in detention)

    For oral inhalation only:

  16. History or presence of atopy or any condition associated with airway hyperresponsiveness (e.g., allergic or non-allergic asthma, chronic obstructive pulmonary disease (COPD))
  17. FEV1 drop of > 10% after inhalation of 4 mL of ALX-0171 placebo (measured at 5 min after the end of inhalation)
  18. Contra-indication for sputum induction, such as (but not limited to) recent eye surgery, recent fractured ribs and recent (or history of) pneumothorax
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01875926

Locations
Belgium
Antwerp, Belgium
Sponsors and Collaborators
Ablynx
Investigators
Study Director: Steven De Bruyn, MD Ablynx NV
  More Information

No publications provided

Responsible Party: Ablynx
ClinicalTrials.gov Identifier: NCT01875926     History of Changes
Other Study ID Numbers: ALX-0171-1.3/13, 2013-001425-71
Study First Received: June 10, 2013
Last Updated: January 2, 2014
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP

Additional relevant MeSH terms:
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on August 20, 2014